On August 2, 2022 KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, reported that Richard W. Pascoe, Executive Chairman of KemPharm, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022, in Boston (Press release, KemPharm, AUG 2, 2022, View Source [SID1234617294]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details regarding KemPharm’s presentations are as follows:
Event: Canaccord Genuity 42nd Annual Growth Conference
Date: August 10, 2022
Time: 4:30 p.m., ET
Location: InterContinental Boston, Boston, MA
Management will be available for one-on-one meetings with registered attendees. A live webcast of the presentation will be available under the "Events & Presentations" within the Investor Relations section of the Company’s website at View Source